-$0.78 EPS Expected for Cellular Biomedicine Group Inc (NASDAQ:CBMG) This Quarter

Share on StockTwits

Equities research analysts expect that Cellular Biomedicine Group Inc (NASDAQ:CBMG) will announce earnings of ($0.78) per share for the current quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Cellular Biomedicine Group’s earnings, with the highest EPS estimate coming in at ($0.64) and the lowest estimate coming in at ($0.91). Cellular Biomedicine Group posted earnings per share of ($0.45) during the same quarter last year, which suggests a negative year-over-year growth rate of 73.3%. The business is expected to announce its next quarterly earnings results on Tuesday, February 18th.

According to Zacks, analysts expect that Cellular Biomedicine Group will report full-year earnings of ($2.75) per share for the current year, with EPS estimates ranging from ($2.87) to ($2.64). For the next year, analysts forecast that the company will report earnings of ($2.83) per share, with EPS estimates ranging from ($3.12) to ($2.58). Zacks’ earnings per share calculations are an average based on a survey of sell-side research analysts that cover Cellular Biomedicine Group.

Several equities analysts recently weighed in on CBMG shares. Robert W. Baird downgraded Cellular Biomedicine Group from an “outperform” rating to a “neutral” rating and reduced their target price for the stock from $26.00 to $19.00 in a research report on Tuesday, November 12th. ValuEngine upgraded Cellular Biomedicine Group from a “hold” rating to a “buy” rating in a report on Friday. BTIG Research initiated coverage on shares of Cellular Biomedicine Group in a research note on Tuesday, September 17th. They set a “buy” rating and a $19.00 price objective for the company. Finally, BidaskClub upgraded shares of Cellular Biomedicine Group from a “sell” rating to a “hold” rating in a report on Wednesday, October 16th. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $21.67.

Shares of NASDAQ:CBMG opened at $17.91 on Friday. Cellular Biomedicine Group has a 52 week low of $10.98 and a 52 week high of $20.60. The business has a fifty day simple moving average of $17.17 and a 200-day simple moving average of $15.05.

Hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. raised its position in shares of Cellular Biomedicine Group by 16.0% in the 2nd quarter. BlackRock Inc. now owns 749,694 shares of the biotechnology company’s stock worth $12,394,000 after buying an additional 103,540 shares during the period. Platinum Investment Management Ltd. increased its stake in Cellular Biomedicine Group by 2.9% during the second quarter. Platinum Investment Management Ltd. now owns 672,885 shares of the biotechnology company’s stock worth $11,123,000 after acquiring an additional 19,170 shares during the last quarter. Sumitomo Mitsui Trust Holdings Inc. increased its stake in Cellular Biomedicine Group by 5.6% during the third quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 557,752 shares of the biotechnology company’s stock worth $8,288,000 after acquiring an additional 29,334 shares during the last quarter. Nikko Asset Management Americas Inc. raised its holdings in shares of Cellular Biomedicine Group by 4.8% in the 3rd quarter. Nikko Asset Management Americas Inc. now owns 557,752 shares of the biotechnology company’s stock worth $8,288,000 after purchasing an additional 25,434 shares during the period. Finally, ARK Investment Management LLC raised its holdings in shares of Cellular Biomedicine Group by 10.0% in the 2nd quarter. ARK Investment Management LLC now owns 314,378 shares of the biotechnology company’s stock worth $5,197,000 after purchasing an additional 28,616 shares during the period. Institutional investors and hedge funds own 22.02% of the company’s stock.

About Cellular Biomedicine Group

Cellular Biomedicine Group, Inc, a clinical stage biopharmaceutical company, develops therapies for cancer and degenerative diseases in Greater China. It focuses on developing and marketing cell-based therapies to treat various diseases, such as cancer and orthopedic diseases. The company develops treatments utilizing proprietary cell based technologies, including immune cell therapy for treating a range of cancer indications comprising technologies in chimeric antigen receptor modified T cells (CAR-T), a genetically modified T-cell receptors (TCRs), and next generation neoantigen-reactive tumor infiltrating lymphocytes; and human adipose-derived mesenchymal progenitor cells for the treatment of joint diseases.

Featured Story: What is the definition of market timing?

Get a free copy of the Zacks research report on Cellular Biomedicine Group (CBMG)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Cellular Biomedicine Group (NASDAQ:CBMG)

Receive News & Ratings for Cellular Biomedicine Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellular Biomedicine Group and related companies with MarketBeat.com's FREE daily email newsletter.